Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus SSRI vs SSRI alone for depression with suicidal ideation (NIRS-based evaluation)
ChiCTR2500095899Phase 4Not yet recruiting
- Sponsor
- Huzhou Third People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Huzhou Third People's Hospital. Primary endpoints: Hamilton Rating Scale for Depression (HAMD-17) and Columbia-Suicide Severity Rating Scale (C-SSRS). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500095899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095899.